Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Scientists grow miniature human myelomas in shell-less chicken eggs to study multiple myeloma

Multiple myeloma is an incurable cancer of the bone marrow. To date, no screening systems have been available to examine the effects of new drugs in a 3D environment. Researchers on the EU project OPTATIO might now fill this gap. They succeeded in growing miniature human myelomas in shell-less chicken eggs in order to screen new marine compounds for anti-myeloma activity.

5 May 2015

Cardio3 BioSciences reports absence of short term adverse events in first patient following NKG2D CAR T-cell infusion

Cardio3 BioSciences, soon to be renamed Celyad, a leader in engineered cell-therapy treatments today announced the infusion of the first patient enrolled in the Company’s Phase I clinical trial evaluating the safety and feasibility of its NKG2D CAR T-cell therapy, in cancer patients suffering from acute myeloid leukemia (AML) or multiple myeloma (MM).

22 Apr 2015

$HSCT increases fracture risk$

HSCT increases fracture risk

Fracture incidence is greatly increased in individuals who undergo haematopoietic stem cell transplantation compared with the general US population, research shows.

20 Apr 2015

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug.

15 Apr 2015

Cardio3 BioSciences announces first patient enrollment in NKG2D CAR T-Cell Phase I clinical trial

Cardio3 BioSciences (C3BS), a leader in engineered cell-therapy treatments with clinical programs initially targeting indications in cardiovascular disease and oncology, today announced the enrollment of the first patient in a Phase I clinical trial evaluating the Company’s lead CAR T-Cell therapy, NKG2D CAR T-Cell, in blood cancer patients with acute myeloid leukemia (AML) or multiple myeloma (MM).

15 Apr 2015

BioLight Life Sciences announces first IOPtiMate™ system sale in Hungary

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate™ system to a medical center located in Hungary.

14 Apr 2015

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.

13 Apr 2015

Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

An innovative clinical trial using the science of "personalized" cellular therapy has begun enrolling children and adults suffering from graft-versus-host-disease (GVHD), a life-threatening complication of bone marrow transplantation in which donor immune lymphocytes attack the organs of the bone marrow transplant recipient.

3 Apr 2015

BioLight forms strategic partnership with Rock-One to expand its presence within China

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today an agreement to enter into a strategic partnership with Rock-One International Holdings Ltd., a holding company specializing in investment activities, including in the high tech and biomedical industries.

2 Apr 2015

Selvita commences IND-enabling studies for its first oncology drug candidate

Selvita, the largest drug discovery company in Central and Eastern Europe, announced today that it is commencing IND-enabling studies for SEL24 project, the company’s first oncology drug candidate.

1 Apr 2015

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy.

30 Mar 2015

CASI receives CFDA approval for ENMD-2076 Phase 2 clinical trial in ovarian clear cell carcinoma

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that the China Food and Drug Administration (CFDA) has approved the Company's application to conduct a Phase 2 global clinical trial in ovarian clear cell carcinoma (OCCC) patients for its proprietary drug candidate ENMD-2076.

30 Mar 2015

UCSF professor wins Vilcek Prize in Biomedical Science

Peter Walter was chosen as winner of the Vilcek Prize in Biomedical Science for his pioneering work on how proteins are transported between cellular compartments and for unraveling the components of a regulatory mechanism that cells use to handle stress tied to the aggregation of misshapen proteins.

29 Mar 2015

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that it has initiated a Phase 2 trial of its target therapy drug candidate ENMD-2076 in triple-negative breast cancer (TNBC) at the Cancer Hospital of Chinese Academy of Medical Sciences in Beijing, China.

25 Mar 2015

Researchers successfully generate cells of immune system to target, destroy cancer cells

Researchers at the Max Delbrück Center for Molecular Medicine Berlin-Buch and Charité - Universitätsmedizin Berlin, Campus Berlin-Buch, have succeeded in generating cells of the immune system to specifically target and destroy cancer cells.

20 Mar 2015

Janssen announces acquisition of XO1

Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired XO1 Limited, a privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab.

19 Mar 2015

Vaxil Bio's ImMucin receives EMA orphan drug designation for treatment of Multiple Myeloma

Vaxil Bio, a leading developer of immunotherapeutic products to treat cancer and infectious diseases, reports today that its lead drug candidate, ImMucin has received orphan drug designation from the European Medicines Agency of the European Commission for the treatment of Multiple Myeloma (MM), a blood cancer.

16 Mar 2015

Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs).

12 Mar 2015

One World Cannabis, Sheba Academic Medical Center ink collaboration agreement

OWC Pharmaceutical Research Corp.'s wholly owned subsidiary One World Cannabis Ltd. signed a collaboration agreement with Sheba Academic Medical Center, the largest hospital in Israel and in the Middle East.

11 Mar 2015

Kyprolis demonstrates superiority over velcade in patients with relapsed multiple myeloma in head-to-head endeavor trial

Patients Receiving Kyprolis Lived Twice as Long without Disease Progression

2 Mar 2015

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Scientists grow miniature human myelomas in shell-less chicken eggs to study multiple myeloma

Cardio3 BioSciences reports absence of short term adverse events in first patient following NKG2D CAR T-cell infusion

HSCT increases fracture risk

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

Cardio3 BioSciences announces first patient enrollment in NKG2D CAR T-Cell Phase I clinical trial

BioLight Life Sciences announces first IOPtiMate™ system sale in Hungary

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

BioLight forms strategic partnership with Rock-One to expand its presence within China

Selvita commences IND-enabling studies for its first oncology drug candidate

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

CASI receives CFDA approval for ENMD-2076 Phase 2 clinical trial in ovarian clear cell carcinoma

UCSF professor wins Vilcek Prize in Biomedical Science

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

Researchers successfully generate cells of immune system to target, destroy cancer cells

Janssen announces acquisition of XO1

Vaxil Bio's ImMucin receives EMA orphan drug designation for treatment of Multiple Myeloma

Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

One World Cannabis, Sheba Academic Medical Center ink collaboration agreement

Kyprolis demonstrates superiority over velcade in patients with relapsed multiple myeloma in head-to-head endeavor trial

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in